phase readout
saveNCT06896916: Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
community read0 votes
Sponsor: AbbVie. Phase: PHASE1. Conditions: Multiple Myeloma
view source ↗Data sources
last refreshed 3h ago
Found something off?
same company · ±60 days · 6
- earningsAbbVie Inc. earningsOct 30, 2026
- earningsAbbVie Inc. earningsOct 29, 2026
- earningsAbbVie Inc. earningsJul 31, 2026
- earningsAbbVie Inc. earningsJul 30, 2026
- phase 1 2 completionblinatumomab: AbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026
- phase 1 2 completionvenetoclax: AbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026
related news · 7
- biopharma dive3 takeaways from a European obesity scientific meeting
- fiercebiotechBMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
- fiercebiotechAbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
- biospaceMyriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
- fiercebiotechAkeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
- biospaceAbbVie shares pressured as Q2 I&I beat falls below investor expectations
- biospaceLilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
🐶 often sniffed alongside
top 8- tagApproval168 co-mentions · 84 sources
- drugHUMIRA122 co-mentions · 61 sources
- drugadalimumab122 co-mentions · 61 sources
- drugABRILADA61 co-mentions · 61 sources
- drugYUSIMRY61 co-mentions · 61 sources
- drugAMJEVITA61 co-mentions · 61 sources
- drugSKYRIZI46 co-mentions · 23 sources
- drugrisankizumab46 co-mentions · 23 sources
comments(0)
5-min edit window · permanent after that